TG Therapeutics (NASDAQ:TGTX) Director Sagar Lonial Sells 20,852 Shares

Key Points

• TG Therapeutics Director Sagar Lonial sold 20,852 shares at an average price of $32.24, resulting in a total transaction amount of $672,268.48, reducing his position by 18.15%.
• The company reported quarterly earnings of $0.17 EPS, missing the consensus estimate of $0.32, while revenue increased 92.1% year-over-year, totaling $141.15 million.
• Goldman Sachs upgraded TG Therapeutics shares to a "hold" rating with a $37.00 price target, while analysts have a consensus rating of "Moderate Buy" and a target price of $46.25.

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) Director Sagar Lonial sold 20,852 shares of the business's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the transaction, the director directly owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

TG Therapeutics Stock Up 0.2%

NASDAQ:TGTX traded up $0.05 during mid-day trading on Wednesday, hitting $32.04. 2,126,702 shares of the company's stock traded hands, compared to its average volume of 1,970,661. TG Therapeutics, Inc. has a twelve month low of $21.16 and a twelve month high of $46.48. The company has a market capitalization of $5.08 billion, a P/E ratio of 86.59 and a beta of 1.88. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The company has a fifty day moving average of $32.11 and a 200 day moving average of $35.68.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business's revenue was up 92.1% on a year-over-year basis. During the same quarter last year, the business earned $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of several research reports. B. Riley boosted their price objective on TG Therapeutics from $53.00 to $55.00 and gave the stock a "buy" rating in a research note on Wednesday. The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a report on Thursday, July 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $48.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TGTX. CWM LLC raised its stake in shares of TG Therapeutics by 16.2% in the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock valued at $82,000 after buying an additional 290 shares during the period. Teacher Retirement System of Texas increased its stake in TG Therapeutics by 1.0% in the 2nd quarter. Teacher Retirement System of Texas now owns 40,212 shares of the biopharmaceutical company's stock worth $1,447,000 after acquiring an additional 417 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 433 shares during the last quarter. Kingswood Wealth Advisors LLC increased its position in shares of TG Therapeutics by 6.4% during the 2nd quarter. Kingswood Wealth Advisors LLC now owns 8,284 shares of the biopharmaceutical company's stock valued at $298,000 after purchasing an additional 500 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of TG Therapeutics by 0.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 63,400 shares of the biopharmaceutical company's stock worth $2,282,000 after acquiring an additional 500 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.